Change - Announcement of Cessation::Resignation of Chief Executive Officer and Executive Director

Issuer & Securities

Issuer/ Manager
AJJ MEDTECH HOLDINGS LIMITED
Securities
AJJ MEDTECH HOLDINGS LIMITED - SG0584008601 - 584
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
04-May-2026 21:26:18
Status
New
Announcement Sub Title
Resignation of Chief Executive Officer and Executive Director
Announcement Reference
SG260504OTHRZGWN
Submitted By (Co./ Ind. Name)
Dr Zhang Jian
Designation
Chairman and Executive Director
Description (Please provide a detailed description of the event in the box below)
Cessation of Ms. Zhao Xin as Chief Executive Officer and Executive Director.

Ms Zhao Xin ("Ms Zhao") has stepped down from her roles as Chief Executive Officer ("CEO") and Executive Director of the Company with effect from 15 May 2026.

The Board wishes to place on record its sincere appreciation to Ms Zhao for her leadership and significant contributions during her tenure. Under her leadership, the Group has:
- strengthened its corporate governance and internal control framework;
- advanced an integrated healthcare technology platform; and
- established foundational capabilities across medical technology, digital healthcare and platform-based development.

Ms Zhao has been an integral part of the Company's leadership development framework. Upon graduating from Nanyang Technological University, she joined the Group and underwent continuous and structured leadership development under the Group's talent development framework, including the completion of executive leadership programmes at Harvard Business School, reflecting the Group's long-term commitment to human capital development, structured leadership succession planning and the development of globally-oriented leadership capabilities.

During her approximately six-year tenure, Ms Zhao, together with the Board, played a key role in shaping and embedding a corporate culture centred on "fairness, transparency, professionalism and integrity".

The Board confirms that there are no disagreements between Ms Zhao and the Board, and that there are no matters relating to her cessation that need to be brought to the attention of shareholders of the Company.

To ensure strategic continuity and retention of institutional knowledge, Ms Zhao will continue to support the Company in a strategic and senior advisory capacity. This role will be non-executive in nature and will not involve participation in management decision-making or day-to-day operations, and may include participation in strategic discussions, where appropriate (without voting rights).

This announcement has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST"), and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626) at 160 Robinson Road, #20-01/02, SBF Center, Singapore 068914.

Additional Details

Name of person
Zhao Xin
Age
37
Is effective date of cessation known?
Yes
If yes, please provide the date.
15/05/2026
Detailed reason(s) for cessation
Ms. Zhao has tendered her resignation letter as Chief Executive Officer and Executive Director of the Company due to personal reasons.

Ms. Zhao is currently serving the requisite notice period and her last day of employment will be 15 May 2026. The Company would like to express its gratitude and appreciation for Ms. Zhao's valuable contributions to the Company during her tenure as Chief Executive Officer and Executive Director.

The Company's Sponsor, after having interviewed with Ms. Zhao is satisfied that, save as disclosed in the announcement, there are no material reasons for her resignation.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of appointment to current position
20/01/2020
Job title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer and Executive Director
Role and responsibilities
General management, overall strategic planning and direction of the Group.
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of independent directors currently resident in Singapore (taking into account this cessation)
3
Do independent directors make up at least one-third of the board (taking into account this cessation)?
Yes
Number of cessations of appointments specified in Mainboard Rule 704(7) or Catalist Rule 704(6) over the past 12 months
3
Shareholding interest in the listed issuer and its subsidiaries
Yes
Shareholding details
39,773,000 ordinary shares held in AJJ Medtech Holdings Limited
Familial relationship with any director and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil
Other Directorships
Past (for the last 5 years)
Nil
Present
1. AJJ Healthcare Management Pte. Ltd.
2. Quest Asia Technologies Pte. Ltd.
3. ESO Health Child Care Pte. Ltd.